机构:[1]Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China[2]Department of Gynecologic Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China[3]Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing, China[4]Department of Gynecology Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, Chengdu, China四川省肿瘤医院[5]Department of Gynecology, Liaoning Cancer Hospital & Institute, Shenyang, China[6]Department of Gynecological Surgery, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[7]Department of Gynecology Oncology, Shandong Cancer Hospital & Institute, Jinan, China[8]Department of Gynecology Oncology, Yunnan Cancer Hospital & The Third Affliated Hospital of Kunming Medical University, Kunming, China[9]Department of Radiation Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China[10]Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[11]Comprehensive Internal Medicine, Shanxi Cancer Hospital, Taiyuan, China[12]Department of Gynecology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[13]Gynecological Oncology, Guangxi Medical University Cancer Hospital, Nanning, China[14]Department of Gynecology Oncology, Cancer Center Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[15]Department of Gynecology Oncology, Hubei Cancer Hospital, Wuhan, China[16]Department of Gynecology Oncology, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China[17]Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China
第一作者机构:[1]Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
推荐引用方式(GB/T 7714):
Wu X.,Xia L.,Zhang K.,et al.Camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy in women with recurrent or metastatic cervical cancer[J].ANNALS OF ONCOLOGY.2023,34:S1284-S1285.doi:10.1016/j.annonc.2023.10.038.
APA:
Wu, X.,Xia, L.,Zhang, K.,Tang, Y.,Zhang, G. N....&Wang, Q..(2023).Camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy in women with recurrent or metastatic cervical cancer.ANNALS OF ONCOLOGY,34,
MLA:
Wu, X.,et al."Camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy in women with recurrent or metastatic cervical cancer".ANNALS OF ONCOLOGY 34.(2023):S1284-S1285